🇨🇳 The mixed story on GLP1s in China

How can partnerships mix with a focus on compounding and generics?

China’s population is currently hovering around 1.4 billion people.

With so much of the mainstream media news flow focusing on GLP1s in the US and western countries, it’s easy to forget about immensely populous nations like China and India that have many people who could benefit from GLP1s.

We dive into two recent seemingly contradictory developments in the GLP1 China ecosystem: new partnerships and a gearing up of generics.